Last reviewed · How we verify

Botulinum toxin A (GSK1358820) — Competitive Intelligence Brief

Botulinum toxin A (GSK1358820) (Botulinum toxin A (GSK1358820)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Botulinum toxin. Area: Neurology; Aesthetics.

phase 3 Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa) Neurology; Aesthetics Small molecule Live · refreshed every 30 min

Target snapshot

Botulinum toxin A (GSK1358820) (Botulinum toxin A (GSK1358820)) — GlaxoSmithKline. Botulinum toxin A blocks acetylcholine release at the neuromuscular junction by cleaving SNARE proteins, causing temporary muscle paralysis.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Botulinum toxin A (GSK1358820) TARGET Botulinum toxin A (GSK1358820) GlaxoSmithKline phase 3 Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
Dysport® (abobotulinumtoxinA) Dysport® (abobotulinumtoxinA) Seoul National University Hospital marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinum Toxin A Onabotulinum Toxin A Walter Reed National Military Medical Center marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
Onabotulinumtoxina for Injection Onabotulinumtoxina for Injection University of Pennsylvania marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
OnabotulinumtoxinA 145 UNT [Botox] OnabotulinumtoxinA 145 UNT [Botox] Beth Israel Deaconess Medical Center marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)
Botox 100 UNT Injection Botox 100 UNT Injection Brigitte Schürch marketed Botulinum toxin type A SNAP-25 (synaptosome-associated protein of 25 kDa)
Abobotulinum toxin A Abobotulinum toxin A Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau marketed Botulinum toxin SNAP-25 (synaptosome-associated protein of 25 kDa)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Botulinum toxin class)

  1. Galderma R&D · 2 drugs in this class
  2. Hexsel Dermatology Clinic · 2 drugs in this class
  3. Seoul National University Hospital · 2 drugs in this class
  4. University of Utah · 2 drugs in this class
  5. Daewoong Pharmaceutical Co. LTD. · 2 drugs in this class
  6. EuBiologics Co.,Ltd · 1 drug in this class
  7. Allergan · 1 drug in this class
  8. GlaxoSmithKline · 1 drug in this class
  9. Beth Israel Deaconess Medical Center · 1 drug in this class
  10. Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Botulinum toxin A (GSK1358820) — Competitive Intelligence Brief. https://druglandscape.com/ci/botulinum-toxin-a-gsk1358820. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: